The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Cyclerion Therapeutics announced results from its Phase 1 translational pharmacology study of IW-6463, the first soluble guanylate cyclase (sGC) ...
read more
Harmony Biosciences announced the FDA has approved WAKIX for cataplexy in adult patients with narcolepsy.
read more
Tuesday, October 20, 2020
Cyclerion announced top-line results from its study of olinciguat, a once daily, vascular sGC stimulator for the potential treatment of sickle cell ...
read more
Tuesday, October 20, 2020
RedHill announced that the FDA has granted Orphan Drug Designation to RHB-204 for nontuberculous mycobacteria disease.
read more
Wednesday, October 21, 2020
EBS has been granted USPN 10,758,507 for novel therapeutic formulations in the treatment of a range of respiratory diseases with significant unmet ...
read more
Wednesday, October 21, 2020
Regulus Therapeutics announced initiation of dosing in its Phase 1b clinical study of RGLS4326 in patients with ADPKD.
read more
Wednesday, October 21, 2020
Arch Biopartners has dosed the first patient in the Phase II trial of its lead drug LSALT peptide.
read more
Wednesday, October 21, 2020
AbbVie announced the FDA has provided full approval to VENCLEXTA in combination with azacitidine, or decitabine, or low-dose cytarabine for acute ...
read more
Thursday, October 22, 2020
Affimed and NKMax America have entered into a clinical collaboration agreement to investigate the combination of a CD16A/EGFR-targeted ICE with the ...
read more
Beroni Group has announced successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech.
read more
Oxeia Biopharmaceuticals announced the initiation of a Phase 2 clinical trial of OXE103 for treating concussion.
read more
Kintara announced the execution of an agreement with GCAR for VAL-083's participation in GCAR's Glioblastoma GBM AGILE Study.
read more
Ionis announced the first patients have been dosed with ION541, an investigational antisense medicine being developed as a potential therapy to treat ...
read more
Tuesday, October 27, 2020
STORM Therapeutics has announced STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human ...
read more
Tuesday, October 27, 2020
F2G announced the FDA has granted an additional Breakthrough Therapy Designation to its lead first-in-class candidate, olorofim.
read more